37 citations
,
September 2018 in “Journal of the American Academy of Dermatology” This letter reports a series of cases where the use of ruxolitinib at a lower dose than previously studied led to hair regrowth in patients with severe alopecia areata.
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” This letter discusses the emerging use of Janus kinase inhibitors, specifically oral tofacitinib, for treating alopecia areata in children, but reports no new clinical findings.
49 citations
,
August 2018 in “International Journal of Dermatology” In this phase I study, partial hair regrowth was observed in patients with alopecia universalis using topical JAK inhibitors, though more research is needed to confirm potential as a treatment alternative to clobetasol.
89 citations
,
August 2018 in “JAMA Dermatology” This study found that the level of expected therapeutic regrowth significantly affected hair regrowth outcomes in contact immunotherapy for alopecia areata, suggesting implications for patient education and adherence.
49 citations
,
May 2018 in “Journal of the American Academy of Dermatology” This letter discusses the limited treatment options for pediatric alopecia areata and the lack of controlled studies for therapies like systemic and off-label immunosuppressive drugs, without reporting new clinical results.
4 citations
,
May 2018 in “European journal of dermatology/EJD. European journal of dermatology” Fumaric acid esters might help treat alopecia areata, but more research is needed.
89 citations
,
March 2018 in “The Journal of Dermatology” This review presents various trichoscopic findings for diagnosing alopecia areata but reports no new clinical results, emphasizing that no single marker is pathognomonic and multiple features should be considered together.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.
28 citations
,
December 2017 in “Lasers in Medical Science” This review assessed evidence on laser therapies for alopecia areata, reporting that the 308-nm excimer laser showed hair regrowth in several studies, while more research is needed for other laser types.
182 citations
,
December 2017 in “Journal of the American Academy of Dermatology” This article reviews current and emerging treatments for alopecia areata, including Janus kinase inhibitors, highlighting variability in clinical outcomes and the lack of sustained remission.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
83 citations
,
June 2017 in “Journal of the American Academy of Dermatology” This study observed that most pediatric patients with alopecia areata experienced some hair regrowth after treatment with topical JAK inhibitors, and the formulations were generally well-tolerated with mild lab abnormalities in some cases.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” This case series found that oral tofacitinib treatment in eight adolescents with alopecia universalis led to significant regrowth of hair, though relapse is likely after stopping therapy.
13 citations
,
January 2017 in “Annals of dermatology/Annals of Dermatology” In this study, simvastatin/ezetimibe treatment led to partial hair regrowth in about 29% of patients with recalcitrant alopecia areata, suggesting it may be a viable alternative therapy for this condition.
14 citations
,
January 2017 in “Skin appendage disorders” This study reported that oral simvastatin/ezetimibe therapy was ineffective for treating alopecia areata, with 67% of participants experiencing no hair regrowth. Additionally, 24% of patients experienced adverse effects, including myalgia, highlighting the need to weigh potential risks against questionable benefits.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.
238 citations
,
November 2016 in “Journal of The American Academy of Dermatology” In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.
196 citations
,
September 2016 in “JCI insight” This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.
51 citations
,
June 2016 in “Journal of the European Academy of Dermatology and Venereology” In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.
17 citations
,
May 2016 in “Archives of Dermatological Research” This study identified specific reflectance confocal microscopy features that help differentiate scarring from non-scarring alopecia, providing a non-invasive diagnostic tool.
31 citations
,
April 2016 in “Journal of the American Academy of Dermatology” Oral dexamethasone may help regrow hair in adults with alopecia totalis and universalis.
14 citations
,
January 2016 in “Annals of dermatology/Annals of Dermatology” This study found that oral cyclosporine was more effective and had fewer side effects than betamethasone minipulse therapy for treating alopecia areata.
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology” This case study reported significant but temporary hair regrowth and skin repigmentation in a patient with vitiligo and alopecia areata during treatment with oral ruxolitinib.
96 citations
,
December 2015 in “JAMA dermatology” This article discusses the potential of topical ruxolitinib as a treatment for alopecia universalis and acknowledges the need for alternatives to systemic JAK inhibitors due to the risk of serious side effects.
41 citations
,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
44 citations
,
February 2015 in “Journal of the American Academy of Dermatology” This study found that combination therapy with diphenylcyclopropenone and anthralin was more effective for complete hair regrowth in chronic extensive alopecia areata than diphenylcyclopropenone alone, despite more common side effects.
14 citations
,
January 2015 in “Annals of dermatology/Annals of Dermatology” This study found that corticosteroid pulse therapy may be more effective than oral cyclosporine with corticosteroid for patients with severe alopecia areata, especially for those with the plurifocal type or a short disease duration.
69 citations
,
January 2015 in “Current problems in dermatology” This review discusses trichoscopy as a noninvasive, effective technique for diagnosing various hair loss conditions and monitoring treatment, highlighting its potential to reduce scalp biopsy necessity.
701 citations
,
August 2014 in “Nature medicine” This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.
72 citations
,
July 2014 in “American journal of clinical dermatology” This review analyzed randomized controlled trials on alopecia areata treatment and found that while several treatments showed effectiveness, most studies had limitations affecting their interpretability.
185 citations
,
June 2014 in “Journal of Investigative Dermatology” This case report describes complete hair regrowth in a patient with alopecia universalis and improved psoriasis after treatment with the oral Janus kinase inhibitor, tofacitinib.
110 citations
,
December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” This article reviews current understanding of alopecia areata, its genetic and immune factors, and discusses ongoing research and treatment development, without presenting new experimental results.
49 citations
,
November 2013 in “JAMA dermatology” This study found that topical clobetasol propionate cream was more effective than hydrocortisone cream in reducing hair loss surface area in children with patchy alopecia areata over 24 weeks, with no serious adverse effects.
33 citations
,
October 2013 in “Cutaneous and ocular toxicology” This article discusses the autoimmune pathogenesis of alopecia areata and reviews the use of immunosuppressive therapies in its treatment, but it does not provide new clinical results.
205 citations
,
April 2013 in “British Journal of Dermatology” In this study, platelet-rich plasma significantly increased hair regrowth and reduced symptoms of alopecia areata compared to triamcinolone acetonide or placebo, with no observed side effects.
218 citations
,
April 2012 in “British Journal of Dermatology” This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.
35 citations
,
June 2011 in “British Journal of Dermatology” This study found that in an Italian population, the HLA-DQB1*03 allele was associated with increased susceptibility to alopecia areata, particularly in cases with more than 50% hair loss.
43 citations
,
May 2011 in “Dermatologic Therapy” This article discusses the phases and histological features of alopecia areata and reports no new clinical findings; the authors emphasize recognizing these phases for accurate diagnosis.
39 citations
,
January 2011 in “Archives of Dermatology” This study found that the yellow dot pattern observed in dermoscopy of alopecia areata corresponds to inefficient follicular structures containing hair remnants, as corroborated by reflectance confocal microscopy and pathological findings.
48 citations
,
January 2011 in “International journal of trichology” This study found that intralesional triamcinolone acetonide was most effective for hair regrowth in localized alopecia areata, with betamethasone valerate foam also being beneficial, while tacrolimus ointment showed no significant effect.
244 citations
,
January 2010 in “Journal of the American Academy of Dermatology” This review discusses treatment options for alopecia areata and suggests tailored treatment plans, noting the challenges posed by spontaneous remission and limited high-quality clinical trials.
50 citations
,
December 2009 in “Journal of The European Academy of Dermatology and Venereology” This study found that latanoprost may be effective for treating eyelash alopecia areata, achieving cosmetically acceptable regrowth in 45% of patients.
43 citations
,
November 2009 in “Archives of dermatology” This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period.
20 citations
,
November 2009 in “European Journal of Dermatology” This study found that topical latanoprost was not effective in treating alopecia areata in eyebrows and eyelashes.
44 citations
,
October 2009 in “Journal of the American Academy of Dermatology” This study reported that 1% bexarotene gel was well tolerated and possibly effective for inducing partial hair regrowth in alopecia areata, but more rigorous trials are needed to confirm its efficacy.
79 citations
,
September 2009 in “Pediatric dermatology” This study found that the 308-nm Excimer laser was effective and safe for treating patchy alopecia areata in children, with hair regrowth observed in 60% of treated scalp patches.
55 citations
,
March 2009 in “Journal of The American Academy of Dermatology” This study found that latanoprost and bimatoprost, when applied cutaneously to the eyelids, did not induce appreciable eyelash regrowth in patients with alopecia areata over 16 weeks.
25 citations
,
December 2008 in “Journal of Dermatological Case Reports” In this study, R-CSLM showed promise in evaluating hair shaft diseases by providing high-quality images of hair structures, although further development is necessary for follicle and perifollicular area analysis.
45 citations
,
July 2008 in “International Journal of Dermatology” This study found that oral sulfasalazine led to varying hair regrowth outcomes in patients with persistent alopecia areata, with 56.3% showing moderate to good responses.
196 citations
,
June 2008 in “International Journal of Dermatology” This study found that dermoscopic indicators like black dots and tapering hairs are valuable markers for diagnosing and assessing the severity and activity of alopecia areata in Asian patients.
286 citations
,
August 2007 in “Journal of Clinical Investigation” This review examines the interplay of genetics and neuroimmunology in alopecia areata, highlighting its potential to inform broader autoimmunity research, but reports no new findings.
26 citations
,
March 2007 in “Clinical and experimental dermatology” Pimecrolimus cream is not effective for treating alopecia areata.
69 citations
,
December 2006 in “Archives of dermatology” This entry contains no research abstract, so no scientific findings or conclusions are reported.
114 citations
,
October 2006 in “Journal of the European Academy of Dermatology and Venereology” In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.
100 citations
,
July 2006 in “British Journal of Dermatology” This study found that intralesional triamcinolone acetonide injections using a needleless injector led to rapid hair regrowth in patients with limited alopecia areata, while lasting growth was rare in alopecia totalis.
63 citations
,
January 2006 in “Journal of cosmetic and laser therapy” This study found that pulsed infrared diode laser therapy (904 nm) was effective in promoting hair regrowth in 94% of patients with resistant patches of alopecia areata.
75 citations
,
June 2005 in “Archives of Dermatology” In this case report, a patient experienced a recurrence of alopecia areata while undergoing etanercept treatment, suggesting the drug may not effectively prevent this condition's return.
141 citations
,
February 2005 in “Journal of the American Academy of Dermatology” In this study, oral prednisolone pulse therapy led to significant hair regrowth in some patients with extensive alopecia areata, whereas no improvement was seen in the placebo group.
85 citations
,
November 2004 in “Journal of the American Academy of Dermatology” The 308-nm excimer laser helps hair regrowth in some alopecia areata cases but not all.
146 citations
,
July 2003 in “Journal of the American Academy of Dermatology” In this study, clobetasol propionate 0.05% ointment was found to induce hair regrowth in 28.5% of patients with severe alopecia areata under occlusive conditions, though long-term benefit was limited to 17.8%.
49 citations
,
January 2003 in “American Journal of Clinical Dermatology” This review discusses various pediatric hair loss conditions and treatments, highlighting the importance of a holistic approach and noting that no single treatment is universally effective.
62 citations
,
April 2002 in “Journal of the American Academy of Dermatology” In this study, sulfasalazine treatment resulted in cosmetically acceptable hair regrowth in 23% of patients with severe alopecia areata in whom a response could be determined.
65 citations
,
September 1999 in “The Journal of Dermatology” In this study, complete to excellent hair regrowth was observed in 63.3% of patients with extensive alopecia areata treated with biweekly dexamethasone pulses, although mild side effects were frequent.
132 citations
,
November 1998 in “Journal of the American Academy of Dermatology” This review evaluates the efficacy and safety of topical sensitizers in treating alopecia areata but reports no new clinical findings.
122 citations
,
November 1998 in “Archives of Dermatology” This study found that aromatherapy involving essential oils significantly improved symptoms of alopecia areata compared to carrier oils alone in a randomized controlled trial.
30 citations
,
August 1998 in “International Journal of Dermatology” This study found that systemic corticosteroids led to satisfactory hair regrowth in 38.9% of severe alopecia areata patients, but hair fall occurred upon therapy discontinuation or tapering.
117 citations
,
February 1996 in “International Journal of Dermatology” This study found that monthly oral prednisolone pulses of 300 mg were effective and safe for treating widespread alopecia areata, with 58.3% of patients achieving cosmetically acceptable hair growth.
47 citations
,
September 1995 in “British Journal of Dermatology” This review discusses the complication of vitiligo in patients undergoing diphencyprone sensitization therapy for alopecia universalis and reports no new clinical findings.
101 citations
,
November 1992 in “Archives of Dermatology” In this study, tapering prednisone followed by 2% topical minoxidil helped limit hair loss in some patients with alopecia areata, with 30% to 47% showing over 25% hair regrowth initially.
36 citations
,
March 1989 in “Cleveland Clinic Journal of Medicine” 3% topical minoxidil effectively treats extensive alopecia areata.
109 citations
,
November 1987 in “Archives of dermatology” In this study, 0.5%-1.0% anthralin cream led to a cosmetic response in 25% of patients with severe alopecia areata, despite common side effects like pruritus and erythema.
101 citations
,
March 1987 in “Journal of The American Academy of Dermatology” Minoxidil solution helps hair regrowth in alopecia areata, with 5% being more effective.
104 citations
,
March 1987 in “Journal of The American Academy of Dermatology” Minoxidil helps hair growth in 63.6% of alopecia patients, with 27.3% having excellent results.
37 citations
,
March 1986 in “Acta Dermato Venereologica” In this study, there was no significant difference in hair growth between patients with extensive alopecia areata treated with 1% minoxidil and those receiving a placebo.
63 citations
,
April 1985 in “Journal of the American Academy of Dermatology” This study observed that topical PUVA treatment led to excellent or good hair regrowth in 45.4% of patients with alopecia areata, though many experienced relapse after treatment stopped.
80 citations
,
October 1983 in “BMJ” This study found that 1% topical minoxidil induced significant hair regrowth in patients with alopecia areata, though it was less effective for those with extensive hair loss such as alopecia totalis and universalis.
80 citations
,
November 1975 in “Acta dermato-venereologica” This study found that while some patients with severe alopecia areata responded to high-dose prednisolone, the response was inconsistent and the therapy's risks prevent recommending it for general use.
75 citations
,
September 1971 in “British Journal of Dermatology” This study found that both intralesional triamcinolone acetonide and triamcinolone hexacetonide promote continuous hair growth in alopecia areata, with effects lasting at least 9 months after a single injection.
